This is an automatically generated preview of the abstract you selected.
Luciferase-based in vivo imaging system to detect neoplasia and metastasis
Darlene Jenkins*; Y Hornig; S Yu; Y Oei; PR Contag
Xenogen Corporation, 860 Atlantic Avenue, Alameda, CA *(firstname.lastname@example.org)
The biophotonic in vivo imaging system (IVIS) developed by Xenogen (Alameda, CA) allows for detection and tracking of tumor development in living animals. The system is based on a highly sensitive CCD camera that can detect low levels of visible light emitted from bioluminescent tumor cells injected or growing in vivo. Tumor cells are cotransfected with plasmids encoding firefly luciferase and an antibiotic resistance marker. Stable cell lines are selected for antibiotic resistance and bioluminescence. Various bioluminescent human and mouse cell lines have been generated using prostate, melanoma and breast carcinoma lines. Experiments involving subcutaneous, intravenous and orthotopic xenograft transplantation of luciferase-expressing tumor cells into immune deficient mice will be described. Imaging times of anesthetized animals are short, typically 1-5 minutes, and repeated whole-body images of the same animals over time offer a key advantage over traditional tumor assays in animal studies. These animal models demonstrate that the IVIS system provides a sensitive, non-invasive technology to rapidly screen and monitor primary and metastatic tumors in vivo and to assess anti-neoplastic therapies in living animals.
Return to the list of abstracts